Want to see AU:AHE full AI Analyst Report?
AHE Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$10.85M
Enterprise ValueAU$5.17
Total Cash (Recent Filing)AU$8.09M
Total Debt (Recent Filing)AU$180.92K
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding637,981,000
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$112.30M
Bulls Say, Bears Say
Bulls Say
Platform & NetworkMedAdvisor operates a pharmacy-focused medication management platform and a consumer app, creating two-sided network effects: pharmacies gain workflow tools while patients adopt refill/adherence features. This durable model supports recurring engagements, data leverage and upsell potential across pharmacies and health programs over time.
Free Cash Flow ImprovementReported free cash flow growth of +18.49% suggests the company has begun improving cash conversion, which can extend runway and fund core operations without immediate external financing. If sustained, stronger FCF provides durable flexibility to invest in product, support pharmacies, and absorb near-term losses while pursuing recovery.
Lean Operating StructureA very small headcount implies low fixed personnel costs and operational lean-ness, reducing structural cash burn relative to larger peers. Over months this can preserve runway, allow focused use of capital for core platform maintenance and partnerships, and facilitate rapid pivots or outsourcing as the business repositions.
Bears Say
Steep Revenue DeclineA sustained revenue decline of ~39% signals structural loss of customers, reduced prescription workflow usage, or declining monetization. Over a multi-month horizon this erodes operating leverage, limits ability to invest in product or sales, and increases the risk that remaining revenue cannot support fixed costs or strategic initiatives.
Deep Negative MarginsExtremely negative margins (net margin ~-95%) indicate core operations fail to cover costs at current scale. Persisting losses destroy equity, constrain reinvestment, and require either rapid margin improvement, substantial cost cuts, or new revenue sources to restore sustainable profitability over the coming months.
Stressed Balance SheetNegative shareholders' equity and an extreme debt-to-equity ratio reflect a precarious capital structure that limits access to conventional financing and raises solvency risk. Over a medium-term horizon the company may need recapitalization or asset sales, which could dilute shareholders or disrupt operations if not addressed.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.01 and its highest was AU$0.09 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$10.85M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Aug 27, 2026 which is in 40 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Feb 26, 2026. The company reported AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 637,981,000 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AHE Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$20.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
-209.68%
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.
Oneview Healthcare Chess Depository Interests repr 1
―
PharmX Technologies
―
Alcidion Group Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―